[go: up one dir, main page]

AR133755A1 - KRAS G12D MODULATION COMPOUNDS - Google Patents

KRAS G12D MODULATION COMPOUNDS

Info

Publication number
AR133755A1
AR133755A1 ARP240102388A ARP240102388A AR133755A1 AR 133755 A1 AR133755 A1 AR 133755A1 AR P240102388 A ARP240102388 A AR P240102388A AR P240102388 A ARP240102388 A AR P240102388A AR 133755 A1 AR133755 A1 AR 133755A1
Authority
AR
Argentina
Prior art keywords
kras
compound
modulation compounds
pharmaceutically acceptable
modulation
Prior art date
Application number
ARP240102388A
Other languages
Spanish (es)
Inventor
Chaodi Dai
Juan A Guerrero
Darryl Kato
Scott E Lazerwith
Jonathan William Medley
Thomas C J Mies
Hyung Pyun
- Shiotsu Hayato Jung
Maoqun Tian
William J Watkins
Jennifer R Zhang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR133755A1 publication Critical patent/AR133755A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de la fórmula (J). Una composición farmacéutica que comprende un compuesto de una cualquiera de las reivindicaciones 1 a 75, y un excipiente farmacéuticamente aceptable. Un método para elaborar un medicamento para inhibir la metástasis de cáncer en un sujeto que lo necesita, caracterizado porque se usa un compuesto de una cualquiera de las reivindicaciones 1 a 75, o una sal farmacéuticamente aceptable de este.A compound of formula (J). A pharmaceutical composition comprising a compound of any one of claims 1 to 75, and a pharmaceutically acceptable excipient. A method for preparing a medicament for inhibiting cancer metastasis in a subject in need thereof, characterized in that a compound of any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof, is used.

ARP240102388A 2020-03-06 2024-09-06 KRAS G12D MODULATION COMPOUNDS AR133755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063562155P 2020-03-06 2020-03-06
US202063640100P 2020-04-29 2020-04-29
US202363581551P 2023-09-08 2023-09-08

Publications (1)

Publication Number Publication Date
AR133755A1 true AR133755A1 (en) 2025-10-29

Family

ID=97521978

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102388A AR133755A1 (en) 2020-03-06 2024-09-06 KRAS G12D MODULATION COMPOUNDS

Country Status (1)

Country Link
AR (1) AR133755A1 (en)

Similar Documents

Publication Publication Date Title
MX2022012714A (en) INHIBITORS OF THE REPLICATION OF NOROVIRUS AND CORONAVIRUS.
AR132007A1 (en) COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K
UY39529A (en) NEW ANTIVIRAL AGENTS DERIVED FROM SPIROPYRROLIDINE
CO2024001367A2 (en) Antiviral compounds
AR132338A1 (en) RAS INHIBITORS
CL2021003202A1 (en) Pyrrolidine compounds
AR133988A1 (en) RAS-PI3K INHIBITORS AND THEIR USES
AR134265A1 (en) HETEROCYCLES AND THEIR USES
CO2021014210A2 (en) Pyrrole compounds
AR127247A1 (en) CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS
ECSP22032016A (en) IRAQ INHIBITOR AND METHOD OF PREPARATION THEREOF AND USE THEREOF
CO2021017202A2 (en) tricyclic compounds
AR074309A1 (en) ANTI-INFLAMMATORY COMPOUNDS AND THEIR PHARMACEUTICAL, DENTIFRICAL AND ADHESIVE COMPOSITIONS. METHOD
CO2026000093A2 (en) Pharmaceutical compositions for nek7 kinase inhibitors
AR127496A1 (en) CD73 COMPOUNDS
AR133755A1 (en) KRAS G12D MODULATION COMPOUNDS
MX2022005199A (en) SSAO INHIBITORS AND USE THEREOF.
AR133133A1 (en) COMPOUNDS THAT MODULATE KRAS
AR132408A1 (en) COMPOUNDS THAT MODULATE KRAS
AR133135A1 (en) COMPOUNDS THAT MODULATE KRAS
MX2024004551A (en) Inhibitors of human immunodeficiency virus replication.
AR105400A1 (en) JAK1 INHIBITORS
AR128894A1 (en) KRAS INHIBITORS
AR134197A1 (en) COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASE
AR129171A1 (en) HETEROAROMATIC COMPOUNDS